The article provides a clinical case of a 58-year-old man with the fi rst clinical manifestation of chronic heart failure in the presence of a signifi cant decrease in the left ventricular ejection fraction. Left ventricular non-compaction cardiomyopathy was diagnosed by echocardiography. After 12 months, a cardiac contractility modulation device was implanted to the patient in the presence of disease progression despite optimal medical therapy. We assessed the course of disease, quality of life, exercise tolerance, and myocardial contractility of the patient before and six months after surgery. The methods of assessment were collection of patient complaints, physical examination, electrocardiography (ECG), fi lling out the Minnesota Living with Heart Failure Questionnaire (MLHFQ), sixminute walk test, spiroergometry, and echocardiography.

This review highlights the preclinical and clinical data about a relatively new electrophysiological method for chronic heart failure (CHF) treatment, cardiac contractility modulation (CCM). The review presents efficacy and safety data. An updated information about the capability of CCM to influence the molecular genetic apparatus of the cardiomyocytes is proposed. In addition, the review assesses prospects for application of CCM as a tool for reverse cardiac remodeling in patients with CHF.